← Back to Search

Alkylating agents

Monoclonal Antibody + Chemotherapy for Advanced Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by St. Vincent Medical Center - Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Metastatic cancer considered incurable by standard therapy and for which no higher priority protocol is available
Age: 18 and over
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test the effectiveness of a monoclonal antibody and a chemotherapy drug in treating patients with metastatic cancer.

Who is the study for?
This trial is for adults with metastatic cancer deemed incurable by standard treatments, including those with certain brain tumors like astrocytoma and glioma. Participants must have a life expectancy of at least 2 months and can have varying health statuses. However, they cannot join if they have asthma, emphysema, pulmonary issues, AIDS/HIV or are pregnant.Check my eligibility
What is being tested?
The study is testing the combination of a monoclonal antibody (a type of protein that can target cancer cells) with cyclophosphamide (a chemotherapy drug) to see if it's effective in treating patients with advanced cancers that have spread throughout the body.See study design
What are the potential side effects?
Potential side effects may include allergic reactions to the monoclonal antibody, damage to normal cells leading to various organ dysfunctions due to its tumor-targeting nature, as well as typical chemotherapy-related side effects such as nausea, hair loss, fatigue and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has spread and cannot be cured with standard treatments.
Select...
I am 18 years old or older.
Select...
I do not have fluid in my lungs.
Select...
I do not have AIDS or HIV.
Select...
My lungs are functioning well.
Select...
I do not have emphysema.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

St. Vincent Medical Center - Los AngelesLead Sponsor
3 Previous Clinical Trials
40 Total Patients Enrolled
Charles L. Wiseman, MD, FACPStudy Chair
4 Previous Clinical Trials
64 Total Patients Enrolled

Media Library

Cyclophosphamide (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT00002482 — Phase 1 & 2
Solid Tumors Research Study Groups:
Solid Tumors Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT00002482 — Phase 1 & 2
Cyclophosphamide (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002482 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any recruitment opportunities for the trial?

"According to clinicaltrials.gov, this specific investigation is no longer seeking participants; the trial was initially posted on June 1st 1991 and last amended November 5th 2013. However, there are numerous alternative trials actively recruiting patients currently."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
1991. "Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002482.
All > Ic
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top